Loading...
Cellular Goods PLC
CBX.L•LSE
Healthcare
Medical - Pharmaceuticals
£0.37
£-0.00(-0.53%)
Cellular Goods PLC (CBX.L) Financial Performance & Statements
Review Cellular Goods PLC’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-73.31%
↓ 73.31%
Operating Income Growth
44.54%
↑ 44.54%
Net Income Growth
44.79%
↑ 44.79%
Operating Cash Flow Growth
58.07%
↑ 58.07%
Operating Margin
-4958.26%
↓ 4958.26%
Gross Margin
61.63%
↑ 61.63%
Net Profit Margin
-4922.54%
↓ 4922.54%
ROE
-93.03%
↓ 93.03%
ROIC
-147.33%
↓ 147.33%
Cellular Goods PLC (CBX.L) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Cellular Goods PLC stock.
| Metric | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $17941.00 | $36214.00 | $18107.00 | $31022.00 |
| Cost of Revenue | $7682.00 | $12664.00 | $6232.00 | $13132.00 |
| Gross Profit | $10259.00 | $23550.00 | $11875.00 | $17890.00 |
| Gross Profit Ratio | $0.57 | $0.65 | $0.66 | $0.58 |
| R&D Expenses | $0.00 | $293288.00 | $293288.00 | $0.00 |
| SG&A Expenses | $627078.00 | $1.55M | $480637.00 | $1.83M |
| Operating Expenses | $627078.00 | $1.55M | $774025.00 | $1.83M |
| Total Costs & Expenses | $634760.00 | $1.56M | $780257.00 | $1.84M |
| Interest Income | $26400.00 | $20130.00 | $10065.00 | $3983.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $616820.00 | $43812.00 | -$39586.00 | $122085.00 |
| EBITDA | $0.00 | -$1.52M | $9965.00 | -$1.81M |
| EBITDA Ratio | $0.00 | -$42.09 | $0.55 | -$58.33 |
| Operating Income | -$616819.00 | -$1.52M | -$762050.00 | -$1.81M |
| Operating Income Ratio | -$34.38 | -$42.09 | -$42.09 | -$58.33 |
| Other Income/Expenses (Net) | -$590419.00 | $772215.00 | $9965.00 | $906712.00 |
| Income Before Tax | -$1.21M | -$1.50M | -$752085.00 | -$1.81M |
| Income Before Tax Ratio | -$67.29 | -$41.54 | -$41.54 | -$58.20 |
| Income Tax Expense | -$603618.00 | $95.00 | $48.00 | -$906712.00 |
| Net Income | -$603620.00 | -$1.50M | -$752133.00 | -$1.81M |
| Net Income Ratio | -$33.64 | -$41.54 | -$41.54 | -$58.20 |
| EPS | -$0.001 | -$0.003 | -$0.001 | -$0.004 |
| Diluted EPS | -$0.001 | -$0.003 | -$0.001 | -$0.004 |
| Weighted Avg Shares Outstanding | $537.96M | $568.94M | $568.67M | $501.52M |
| Weighted Avg Shares Outstanding (Diluted) | $537.96M | $589.91M | $568.67M | $507.25M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan